Regeneron climbs as Eylea becomes the little engine that could
By Marie Powers
Wednesday, August 6, 2014
Regeneron Pharmaceuticals Inc. had more good news to crow about Tuesday, reporting that second quarter global net sales of Eylea (aflibercept) increased 53 percent, to $662 million, over the same period a year earlier, including sales of $415 million in the U.S. a 26 percent jump based on a modest decrease in distributor inventory in the second quarter of 2013 and $247 million in the rest of world.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.